vTv Therapeutics to Present at Neuro Advance Boston
October 03 2016 - 7:30AM
Business Wire
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage
biopharmaceutical company committed to the discovery and
development of new orally administered treatments for Alzheimer’s
disease and diabetes, announced today that company Chief
Medical Officer, Dr. Larry Altstiel, MD, PhD, will speak on a panel
at Neuro Advance Boston hosted by Harvard Medical School. Dr.
Altstiel will participate on the panel “Novel Approaches to
Alzheimer’s Disease,” from 9:30 to 10:10am on October
5th. Dr. Altstiel will focus on the novel
mechanism of action behind vTv's lead investigational drug
candidate called azeliragon, which is currently being studied in a
Phase 3 trial for the treatment of mild Alzheimer’s disease.
Azeliragon is a novel orally active small-molecule antagonist of
Receptor for Advanced Glycation Endproducts (“RAGE”). A broad range
of human pathologic and experimental biologic investigation
suggests that RAGE activation contributes to the pathogenesis of
Alzheimer’s disease. Sustained interactions of Amyloid β and other
mediators of inflammation with RAGE at the blood-brain barrier and
in neuronal and microglial cells may play major roles in amyloid
plaque formation, neuroinflammation, and chronic neural dysfunction
– all hallmarks of Alzheimer’s disease.
The Phase 2b results of 5mg per day of azeliragon over a period
of 18 months showed statistically significant benefits in
mild-to-moderate Alzheimer’s patients (+3.1 points on ADAS-Cog11
standard measure of cognition) and greater benefit in mild patients
(+4.0 points on ADAS-Cog11), with improvements on secondary
endpoints including a significant reduction in psychiatric adverse
events.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and Type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161003005286/en/
InvestorsIR@vtvtherapeutics.comorMediaNura Strong, 336-841-0300
X164PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024